One America News (OAN) Interviews Biotricity’s CEO for his Insight into Telemedicine and how Remote Diagnostics can take it Further

CEO discusses how Biotricity’s technology fits into Telemedicine and helps Expand its Use Cases


REDWOOD CITY, Calif., April 23, 2020 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, announced that its CEO, Waqaas Al-Siddiq, was recently interviewed on OAN to discuss Telemedicine and how Biotricity and its Bioflux solution can be used to expand the use cases for Telemedicine.

“It is a privilege to see our technology being used to expand the scope and ability of Telemedicine during these times. Remote Diagnostics, Remote Patient Monitoring and Telemedicine are complementary technologies that together amplify their positive impact in healthcare. Recent events have put a spotlight on the individual benefits of these technologies, but their combination creates a game changing solution for care delivery. As always, no solution is perfect, but these technologies will become more and more common in the coming years,” said Dr. Al-Siddiq.

Remote Diagnostics, Remote Monitoring and Telehealth are technologies that are driving an improvement in care delivery while reducing costs. Recent events have put them front and center, accelerating the use of these technologies. In the coming months and years, we will see an increase in the adoption of these technologies as the focus continues towards reducing costs and improving care.

To watch the interview please visit:

OAN: https://www.youtube.com/watch?v=gciqoYrfApc

To learn more, join our newsletter at: https://www.biotricity.com/contact-us/ or follow on:

Twitter: @biotricity_inc Facebook: facebook.com/biotricity/ or
LinkedIn: linkedin.com/company/biotricity-measuring-vitals

About Biotricity Inc.
Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. To learn more, visit www.biotricity.com.

Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Media Contacts
McCoin & Smith Communications Inc.
Chris McCoin,
Chris@mccoinsmith.com, 508-429-5988
Richard Smith,
rick@mccoinsmith.com, 978-433-3304

Investor Relations:
Biotricity Inc.
1-800-590-4155
investors@biotricity.com